Newsletter

Tillie Vodka

Total Labels 1
Approved 1
Expired 0

3BR Distillery LLC — Keyport, NJ

New Jersey

About Tillie Vodka

Tillie Vodka is a vodka brand originating from New Jersey. According to TTB records, the brand carries a class designation of vodka in the 80-89 proof range. The brand maintains a single product offering within its portfolio. Tillie Vodka received its initial TTB label approval in 2021, marking its entry into the spirits registry. As a New Jersey-based vodka producer, the brand represents the state's presence in the vodka market. The spirit's proof classification places it within the standard range for conventional vodka expressions. With one approved label on record, Tillie Vodka presents a focused product line to consumers seeking vodka options. The brand's registration in the TTB COLA database establishes its legal status and compliance with federal spirits regulations. The 2021 approval date indicates the brand's relatively recent establishment within the formal TTB approval system. Tillie Vodka's New Jersey origin connects it to a state with a notable spirits production presence. The brand's single distinct product grouping suggests a streamlined approach to its market offering. As a vodka within the 80-89 proof category, Tillie represents a standard-strength option in the broader vodka category.

Filter by:
Displaying 1 results
Label Name Spirit Type Status Approval Date Producer
Vodka 80-89 Proof
Tillie Vodka

VODKA 80-89 PROOF

Vodka 80-89 Proof Approved 2021-12-10 3BR Distillery LLC

Page 1 of 1

1

Tillie Vodka at a Glance

Tillie Vodka has 1 distinct product with 1 total TTB label approvals, including Vodka 80-89 Proof. Labels approved between 2021-12-10 and 2021-12-10. Produced in New Jersey.

All information sourced from public TTB records.

Are you the owner or distributor of Tillie Vodka?

Claim this brand listing to update information or get featured. Contact team@buy.vodka.

Produced At

3br Distillery LLC

Related Brands

Related Questions

Browse All Labels

Stay informed

Newsletter coming soon.

Follow us on X for new approvals, launches, and industry intelligence.